AIM ImmunoTech (NYSE:AIM) Shares Up 2.4%

AIM ImmunoTech Inc. (NYSE:AIM) shares shot up 2.4% during trading on Friday . The stock traded as high as $0.37 and last traded at $0.36. 160,471 shares traded hands during mid-day trading, a decline of 32% from the average session volume of 234,326 shares. The stock had previously closed at $0.36.

AIM ImmunoTech Price Performance

The company has a quick ratio of 1.14, a current ratio of 1.14 and a debt-to-equity ratio of 0.23. The firm has a fifty day simple moving average of $0.38 and a 200 day simple moving average of $0.41.

AIM ImmunoTech (NYSE:AIM) last posted its quarterly earnings results on Thursday, May 16th. The company reported ($0.12) EPS for the quarter. The business had revenue of $0.04 million during the quarter. AIM ImmunoTech had a negative net margin of 16,123.32% and a negative return on equity of 191.38%.

Insider Buying and Selling at AIM ImmunoTech

In other AIM ImmunoTech news, CEO Thomas K. Equels purchased 61,729 shares of the stock in a transaction on Monday, May 6th. The stock was bought at an average price of $0.41 per share, for a total transaction of $25,308.89. Following the acquisition, the chief executive officer now directly owns 778,184 shares of the company’s stock, valued at $319,055.44. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. 0.02% of the stock is owned by company insiders.

About AIM ImmunoTech

AIM ImmunoTech Inc, an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's lead product candidate is Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS).